UTR ups its production capability for Electric Vehicle battery material

Published 04-OCT-2017 14:49 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Battery technology company, UltraCharge Limited (ASX:UTR) announced today it will be upscaling its production of nanotube material at its pilot project with one of the world’s leading fully vertically integrated battery energy storage solution providers, Leclanché SA.

UTR has an MOU with Leclanché to seek cost competitive and large-scale manufacturing of a high-cycling, fast-charging and high energy density battery for the electric vehicle market.

The pilot project involves testing and evaluating its titanium dioxide nanotube technology. The technology will replace graphite in anodes (negative pole) with a nanotube gel material made from titanium dioxide, in lithium batteries. This has the potential to revolutionise the market for lithium batteries by producing a battery that is safe, has a longer lifetime and is fast charging.

Leclanché has partnership with Fastned, a Dutch company that is pioneering the roll-out of fast charging stations for electric vehicles (EVs) in Europe. Leclanché has been tasked with developing the battery storage solution.

Leclanché has also signed an agreement with electric bus, or Ebus, manufacturer Skoda Electric, which will see Leclanché provide Skoda with battery solutions for its eBus expansion strategy.

Additionally, the increased nanotube material production capability will assist in meeting growing demand from other end users.

UltraCharge has already demonstrated significant progress in the successful synthesis of its nanofiber anode material using its pilot reactor, producing 50g/day of anode material. To meet the requirements for stage 2 of the project, UTR has ordered a 55L reactor to increase production capacity by 25 times.

The new equipment will enable the production of at least 250kgs of anode material per year. This will be more than enough to meet the higher demand from Leclanché as it continues to test the material in its battery manufacturing plant.

Those considering this stock shouldn’t make assumptions regarding future sales, nor should they base investment decisions on performances to date. Those considering this stock should seek independent financial advice.

This new reactor at UTR’s facility is an important step in delivering on its milestones and business strategy. It will help progress its partnership with Leclanché, and provide additional capacity to meet demand from new customers.

UTR is currently in discussions with several potential clients and remains focused on its strategy to bring its anode technology to market, specifically for use in electric vehicles along with other industrial applications.

UTR CEO, Kobi Ben-Shabat, said “We are making excellent progress on our pilot project with Leclanché, and I am confident that the new reactor will allow us to upscale our production processes and deliver the quantities needed for Leclanché to build a battery prototype for testing. I look forward to updating the market on the results of the testing and the next stage of the project”.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free